Phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a molecular target in lung epithelial wound repair

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1172-1184

  Lai, J P ^a,b   Dalton, J T ^b   Knoell, D L ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Epithelium; Lung; PTEN; Wound remodelling

Indexed keywords

DIPOTASSIUM BISPEROXO (PICOLINATO) OXOVANADATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POTASSIUM BISPEROXO (1,10 PHENANTHROLINE) OXOVANADATE; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG INJURY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; WOUND CLOSURE; WOUND HEALING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; EPITHELIAL CELLS; GLUCOSE-6-PHOSPHATASE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG; ORGANOMETALLIC COMPOUNDS; PHENANTHROLINES; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TIME FACTORS; WOUND HEALING;

EID: 36949030243     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707501     Document Type: Article

References (35)

1. Bao S, Wang Y, Sweeney P, Chaudhuri A, Doseff AI, Marsh CB et al. (2005). Keratinocyte growth factor induces Akt kinase activity and inhibits Fas-mediated apoptosis in A549 lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 288: L36-L42.
2. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, Murray SF et al. (2002). Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51: 1028-1034.
3. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al. (1997). Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000.
4. Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
5. Cerovac Z, Ban J, Morinville A, Yaccato K, Shaver A, Maysinger D (1999). Activation of MAPK by potassium bisperoxo(1,10-phenanthroline) oxovanadate (V). Neurochem Int 34: 337-344.
6. Chan TO, Rittenhouse SE, Tsichlis PN (1999). AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 68: 965-1014.
7. Dahia PL, Marsh DJ, Zheng Z, Zedenius J, Komminoth P, Frisk T et al. (1997). Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57: 4710-4713.
8. Datta PK, Lianos EA (1999). Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Kidney Int 56: 486-493.
9. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST (2003). Airway remodeling in asthma: new insights. J Allergy Clin Immunol 111: 215-225; quiz 226.
10. Franke TF, Kaplan DR, Cantley LC, Toker A (1997). Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 275: 665-668.
11. Gordon JA (1991). Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol 201: 477-482.
12. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J (1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660-3663.
13. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B et al. (1997). Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 272: 843-851.
14. Jain L, Eaton DC (2006). Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol 30: 34-43.
15. Karp PH, Moninger TO, Weber SP, Nesselhauf TS, Launspach JL, Zabner J et al. (2002). An in vitro model of differentiated human airway epithelia. Methods for establishing primary cultures. Methods Mol Biol 188: 115-137.
16. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y et al. (1999). Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99: 323-334.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
18. Lu Y, Parkyn L, Otterbein LE, Kureishi Y, Walsh K, Ray A et al. (2001). Activated Akt protects the lung from oxidant-induced injury and delays death of mice. J Exp Med 193: 545-549.
19. Maehama T, Dixon JE (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378.
20. Mutlu GM, Sznajder JI (2005). Mechanisms of pulmonary edema clearance. Am J Physiol Lung Cell Mol Physiol 289: L685-L695.
21. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G et al. (1994). Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem 269: 4596-4604.
22. Puchelle E, Zahm JM, Tournier JM, Coraux C (2006). Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3: 726-733.
23. Ray P, Devaux Y, Stolz DB, Yarlagadda M, Watkins SC, Lu Y et al. (2003). Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci USA 100: 6098-6103.
24. Ray P (2005). Protection of epithelial cells by keratinocyte growth factor signaling. Proc Am Thorac Soc 2: 221-225.
25. Rumora L, Hadzija M, Maysinger D, Zanic-Grubisic T (2004). Positive regulation of ERK activation and MKP-1 expression by peroxovanadium complex bpV (phen). Cell Biol Toxicol 20: 293-301.
26. Saga Y, Mizukami H, Takei Y, Ozawa K, Suzuki M (2003). Suppression of cell migration in ovarian cancer cells mediated by PTEN overexpression. Int J Oncol 23: 1109-1113.
27. Schmid AC, Byrne RD, Vilar R, Woscholski R (2004). Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 566: 35-38.
28. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. (1998). Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
29. Tamura M, Gu J, Takino T, Yamada KM (1999). Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59: 442-449.
30. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI et al. (1997). Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57: 3935-3940.
31. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000). Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010-5018.
32. Vazquez F, Sellers WR. (2000). The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470: M21-M35.
33. Vinciguerra M, Foti M (2006). PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem 112: 89-104.
34. Weng LP, Brown JL, Eng C (2001). PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 10: 599-604.
35. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ et al. (2000). Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 97: 4233-4238.